CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin D. In this review, we summarize the clinical aspects of CYP3A-mediated metabolism of tacrolimus and vitamin D with emphasis on the influence of single-nucleotide polymorphisms on tacrolimus disposition. We describe the utility of 4β hydroxycholesterol as a marker of CYP3A activity. Then, we discuss the possible interaction between calcineurin inhibitors and vitamin D in solid organ transplant recipients. Also, we review other mechanisms which may contribute to side effects of calcineurin inhibitors on bone. Lastly, suggestions for future research and clinical perspectives are discussed

Additional Metadata
Keywords Calcineurin inhibitors .CYP3A .CYP3A4 .CYP3A5 .Vitamin D . Mineral and bone disorder .Renal transplantation
Persistent URL dx.doi.org/10.1007/s00467-018-4030-3, hdl.handle.net/1765/116796
Journal Pediatric Nephrology
Citation
Prytula, A., Cransberg, K, & Raes, A. (2018). Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?. Pediatric Nephrology, 34(7), 1201–1210. doi:10.1007/s00467-018-4030-3